EBioMedicine (May 2023)

Macrophage CD5L is a target for cancer immunotherapyResearch in context

  • Lidia Sanchez-Moral,
  • Tony Paul,
  • Clara Martori,
  • Joan Font-Díaz,
  • Lucía Sanjurjo,
  • Gemma Aran,
  • Érica Téllez,
  • Julià Blanco,
  • Jorge Carrillo,
  • Masaoki Ito,
  • Martina Tuttolomondo,
  • Henrik J. Ditzel,
  • Caterina Fumagalli,
  • Gustavo Tapia,
  • Julia Sidorova,
  • Helena Masnou,
  • Marco-Antonio Fernández-Sanmartín,
  • Juan-José Lozano,
  • Cristina Vilaplana,
  • Alhelí Rodriguez-Cortés,
  • Carolina Armengol,
  • Annabel F. Valledor,
  • Leonor Kremer,
  • Maria-Rosa Sarrias

Journal volume & issue
Vol. 91
p. 104555

Abstract

Read online

Summary: Background: Reprogramming of immunosuppressive tumor-associated macrophages (TAMs) presents an attractive therapeutic strategy in cancer. The aim of this study was to explore the role of macrophage CD5L protein in TAM activity and assess its potential as a therapeutic target. Methods: Monoclonal antibodies (mAbs) against recombinant CD5L were raised by subcutaneous immunization of BALB/c mice. Peripheral blood monocytes were isolated from healthy donors and stimulated with IFN/LPS, IL4, IL10, and conditioned medium (CM) from different cancer cell lines in the presence of anti-CD5L mAb or controls. Subsequently, phenotypic markers, including CD5L, were quantified by flow cytometry, IF and RT-qPCR. Macrophage CD5L protein expression was studied in 55 human papillary lung adenocarcinoma (PAC) samples by IHC and IF. Anti-CD5L mAb and isotype control were administered intraperitoneally into a syngeneic Lewis Lung Carcinoma mouse model and tumor growth was measured. Tumor microenvironment (TME) changes were determined by flow cytometry, IHC, IF, Luminex, RNAseq and RT-qPCR. Findings: Cancer cell lines CM induced an immunosuppressive phenotype (increase in CD163, CD206, MERTK, VEGF and CD5L) in cultured macrophages. Accordingly, high TAM expression of CD5L in PAC was associated with poor patient outcome (Log-rank (Mantel–Cox) test p = 0.02). We raised a new anti-CD5L mAb that blocked the immunosuppressive phenotype of macrophages in vitro. Its administration in vivo inhibited tumor progression of lung cancer by altering the intratumoral myeloid cell population profile and CD4+ T-cell exhaustion phenotype, thereby significantly modifying the TME and increasing the inflammatory milieu. Interpretation: CD5L protein plays a key function in modulating the activity of macrophages and their interactions within the TME, which supports its role as a therapeutic target in cancer immunotherapy. Funding: For a full list of funding bodies, please see the Acknowledgements.

Keywords